We are very pleased to announce the entry of a new investor into Lxbio Pharmaceuticals S.A., reinforcing the company’s momentum as it moves into its next phase of growth.

Founded in 2021, Lxbio Pharmaceuticals is a Portuguese biopharmaceutical company developing highly innovative therapeutic platforms to address major unmet medical needs, including infectious diseases, oncology, and other complex pathologies.

Our ambition is clear: to transform cutting-edge science into truly differentiated, scalable solutions with global impact.

We proudly welcome the funds Innovation, Research & Creativity (IRC) and Portugal Panorama Capital as new shareholders of Lxbio. Managed by FundBox, these funds have completed their investment at a €100 million company valuation, reflecting strong confidence from the funds and their investors in Lxbio’s scientific platforms, team, and execution capabilities.